The combination of SLC7A11 inhibitor and oridonin synergistically inhibits cervical cancer cell growth by decreasing the NADPH/NADP+ratio  

作　　者：Yajie Liu Pengxing He Xubin Ma Yingqi Tian Yu Zhang Yang Wang Yingjie Jia Hongmin Liu Ying Liu Yichao Xu 

机构地区：[1]Key Laboratory of Advanced Drug Preparation Technologies,Ministry of Education,Co-innovation Center of Henan Province for New Drug R&D and Preclinical Safety,School of Pharmaceutical Sciences,Zhengzhou University,Zhengzhou,Henan 450001,China [2]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan 450052,China

出　　处：《Genes & Diseases》2025年第1期137-140,共4页基因与疾病(英文)

基　　金：supported by the National Key Research and Development Project(China)(No.2018YFE0195100);the National Natural Science Foundation of China(No.82020108030);the Key Scientific Research Projects in Colleges and Universities of Henan Province,China(No.23A350007).

摘　　要：SLC7A11,as the core component of system xc,protects cancer cells from oxidative-stress-induced cell death like ferroptosis by mediating cystine uptake.Recent studies revealed that SLC7A11 is widely overexpressed in various types of cancer,and inhibition of SLC7A11 could inhibit tumor growth.1 Consistently,SLC7A11 was overexpressed in cervical cancer,and the expression of SLC7A11 was associated with the severity of cervical cancer(Fig.1A;Fig.S1A),making SLC7A11 a promising anti-tumor target.However,SLC7A11 inhibitor imidazole ketone erastin(IKE)alone exerts weak antiproliferative effects in cervical cancer cells(Fig.S1D).Oridonin is isolated from the traditional Chinese herbal Rabdosia rubescens and exhibits mild anti-cancer activity against multiple types of tumor cells,including cervical cancer cells.However,the low bioavailability and dose-dependent toxicity of oridonin hinder its clinical application.

关 键 词：CERVICAL HERBAL synergistic 

分 类 号：R73[医药卫生—肿瘤]